UnknownPhase 2/3

Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy

Egypt60 participantsStarted 2019-10-01

Plain-language summary

The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients. Study design: Prospective clinical based study. The aim of this work is to study the effect of N-acetylcysteine (NAC) on proteinuria and on the serum level of lipoprotein a (LPa) in diabetes induced nephropathy in type-2 diabetic patients.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Confirmed diagnosis of Diabetes Mellitus.
✓. Age over 20 years.
✓. Patients with proteinuria ≥ 30 mg /dl.

Exclusion criteria

✕. Patients on lipid lowering medications.
✕. Cigarette smokers.
✕. Presence of liver and heart diseases.

What they're measuring

Lipoprotein (a)

Timeframe: 2 months

Triglycerides

Timeframe: 2 months

Systolic blood pressure

Timeframe: 2 months

Trial details

NCT IDNCT04531163

SponsorAl-Azhar University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-11-01

View on ClinicalTrials.gov More Diabetic Kidney Disease trials